Joseph Monahan, Ph.D., has served as Aclaris’ Chief Scientific Officer since January 2021, and has more than 35 years of pharmaceutical research experience. Previously, Joseph served as Aclaris’ Executive Vice President, Research and Development.
Prior to joining Aclaris, Joseph founded the biotechnology company, Confluence Life Sciences, Inc. in 2010 and functioned as the Chief Scientific Officer. He has also held multiple research leadership positions at Pfizer Inc., including Executive Director, Inflammation Research, global kinase platform leadership team lead; site head of enzymology and biophysics, and inflammation research and development lead. Throughout his career, he led the advancement of project portfolios from early discovery through phase 1 and 2 clinical development. He has held adjunct and visiting professor positions at Washington University Medical School, University of Missouri and University of California, Los Angeles School of Medicine. He has published over 85 peer-reviewed publications and is listed as co-inventor on 14 patents.
Joseph received his Bachelor of Science in biochemistry from the University of New York at Buffalo and Doctor of Philosophy in biochemistry from the University of South Carolina.
What is Joseph Monahan's net worth?
The estimated net worth of Joseph Monahan is at least $1.44 million as of March 2nd, 2023. Dr. Monahan owns 151,261 shares of Aclaris Therapeutics stock worth more than $1,436,980 as of June 7th. This net worth estimate does not reflect any other assets that Dr. Monahan may own. Learn More about Joseph Monahan's net worth.
How do I contact Joseph Monahan?
Has Joseph Monahan been buying or selling shares of Aclaris Therapeutics?
Joseph Monahan has not been actively trading shares of Aclaris Therapeutics during the past quarter. Most recently, Joseph Monahan sold 14,800 shares of the business's stock in a transaction on Thursday, March 2nd. The shares were sold at an average price of $12.37, for a transaction totalling $183,076.00. Following the completion of the sale, the insider now directly owns 151,261 shares of the company's stock, valued at $1,871,098.57. Learn More on Joseph Monahan's trading history.
Who are Aclaris Therapeutics' active insiders?
Are insiders buying or selling shares of Aclaris Therapeutics?
During the last year, Aclaris Therapeutics insiders bought shares 1 times. They purchased a total of 6,500 shares worth more than $50,310.00. During the last year, insiders at the biotechnology company sold shares 13 times. They sold a total of 198,271 shares worth more than $3,015,162.15. The most recent insider tranaction occured on March, 9th when CEO Douglas J Manion bought 6,500 shares worth more than $50,310.00. Insiders at Aclaris Therapeutics own 6.7% of the company.
Learn More about insider trades at Aclaris Therapeutics. Information on this page was last updated on 3/9/2023.
